I Spent 11 Years Writing
the Claims You Believed.
Here's What Was Actually
in the Bottles.
I was good at my job. That's the part that kept me up at night. I knew exactly what the labels didn't say — and I knew exactly how to write around it. This is what I couldn't say then. It's what I'm saying now.
Let me start with something that's going to sound strange coming from someone who spent over a decade in prestige skincare marketing.
I have never bought a skincare product I fully believed in.
Not once. Not in eleven years of writing copy for some of the most recognizable names in the industry. Not when I was crafting the "clinically proven" language. Not when I was finding the right way to say "peptide-rich formula" without ever saying what that actually meant. Not when I was sitting in a product launch meeting, holding a serum that retailed for $140, doing the math in my head on the formulation budget while I smiled and nodded at the campaign brief.
I knew. That's the thing I need you to understand before anything else. The people writing the claims know. The marketing team knows. The brand directors know. Putting 5 parts per million of an active into a product and then building an entire campaign around that active isn't an accident or an oversight. It's a business decision, made in a room, by people who know FDA labeling requirements well enough to use them as cover.
I was one of those people. For eleven years.
I left fourteen months ago, and I've been trying to figure out how to say this publicly ever since.
"Most people use it at 3, 5, maximum 10 ppm of peptide. The rest is just water... any higher than 10 ppm, 0.0001 percent in a cosmetic cream. There is no reason to do it."
— Karl Lintner, Sederma Peptide Chemist · Testimony to the CIR Expert Panel · Johnson et al. 2018Karl Lintner is one of the most respected peptide chemists in the cosmetic industry — not a consumer advocate, an industry insider. And he's describing, in plain language, exactly what every brand you've ever bought is doing with the peptide printed on their label.
Dr. Zoe Diana Draelos confirmed it from the clinical side in Dermatology Times: "Due to expense, peptides are used in a concentration of parts per million."
Here's what parts per million looks like in practice: when you buy a serum listing "4% Matrixyl 3000" on the packaging, that four percent refers to the peptide complex — the carrier solution. The actual peptide content works out to roughly 4 and 2 parts per million of the finished product. That's 0.0004% and 0.0002% of what's in the bottle.
If you've ever stared at an empty bottle thinking: I did everything right. I waited twelve weeks. Nothing moved.
You weren't the problem. The dose was.
What a Product Launch Actually Looks Like From the Inside
I want to walk you through something. Not any specific brand — I'm not here to name names. But a composite of every copper peptide launch I was part of over the past decade, because honestly, the process was almost identical every time.
It starts with the formulation brief. The chemistry team comes back with a cost-per-unit breakdown, and there's always a line item for the active — the peptide, in this case GHK-Cu — and there's always a conversation about that line item. The conversation goes like this: what's the minimum concentration we need to list this as a featured ingredient?
The answer, under current FDA guidelines: it just needs to appear on the INCI list in descending order of concentration. No minimum. No threshold for what "featured" actually means.
So the active goes in at whatever concentration fits inside the margin target. Sometimes 5 ppm. Sometimes 8. Occasionally, if someone pushes back, it gets to 50 ppm — still sub-therapeutic, still pharmacologically inert, but it's on the label, and the label is what the marketing team works from.
Then the brief comes to people like me.
My job was to take the formulation sheet and build a story around the hero ingredient. I was good at it. I knew Pickart's research. I knew the 1973 Nature paper. I knew the plasma GHK-Cu numbers — 200 ng/mL at age 20, down to 80 ng/mL by age 60. I used all of it. I wrote about "restoring what your skin has lost" and "replenishing the signal your body used to send." I wrote those lines while knowing the concentration in the bottle was nowhere near what Pickart's research actually used.
That's the part I can't unknow.
"I keep falling for the packaging and the promises. I know better and I still do it. That's the part that's embarrassing."
— r/30PlusSkinCare · Community thread on peptide serumsI've read that comment. I've read hundreds like it. And I want to say something directly to whoever wrote it: you're not embarrassed because you're naive. You're embarrassed because the system was specifically built to get past your intelligence. Those claims were written by people who knew exactly where your skepticism lived and exactly how to route around it.
I know because I was in those rooms.
The Specific Deception Around Copper Peptides
GHK-Cu — copper tripeptide-1, the molecule Loren Pickart isolated at UCSF in 1973 — became a marketing category around 2018 when The Ordinary launched it in a $32 serum and the skincare community started paying real attention. What happened next was entirely predictable to anyone who'd been inside the industry for more than five minutes.
Every brand with a peptide serum quietly repositioned it around copper peptides. Every brand launching something new added GHK-Cu to the brief. Not at concentrations informed by Pickart's research. At concentrations informed by the cost-per-unit target and the legal minimum required to feature it on the label.
Here are the specific tactics — so you can spot them yourself from now on:
The complex claim. A product lists "4% peptide complex." You read 4% and assume it means the active peptide. It doesn't. It refers to the carrier solution. The actual peptide content is 4 to 2 parts per million of the finished product. I've written this claim. I knew what it meant and what a customer would think it meant. Those aren't the same thing.
The proprietary blend shield. When a brand lists a "proprietary peptide blend" without individual concentrations, they're using the FDA's lack of disclosure requirements as legal cover. There's no regulatory reason they can't disclose. There's a margin reason.
The INCI position trick. At 5 to 10 ppm, the peptide shows up in the same general position as preservatives and fragrance — near the bottom of the list. I've watched brand directors have long arguments about where on the INCI list an active would fall at a given concentration, specifically because they knew customers were checking.
The "clinically studied" end-run. "Clinically studied ingredient" doesn't mean the product has been clinically studied. It means the ingredient has been studied somewhere, at some point, possibly at a concentration that has nothing to do with what's in this bottle. I wrote this claim many times. It's technically defensible. It's functionally misleading. I knew both things at once.
The Molecule That Got Used as Decoration
In 1973, a biochemist named Loren Pickart was working at UCSF, studying why aged tissue responded differently to young plasma versus old plasma. When he exposed liver cells from 60–80-year-old donors to plasma from young donors, the old cells started producing proteins like young cells. They behaved — measurably — as if they'd been reset.
Pickart isolated the signal. A tripeptide: glycine, histidine, and lysine bound to a single copper ion. He called it GHK-Cu. Published in Nature in 1973. PMID 4354173
He spent the next fifty years studying it. Twenty-nine patents. Forty-six peer-reviewed papers. A 2014 analysis found that GHK modulated gene expression across 31.2% of the 13,424 human genes analyzed. BioMed Res Intl 2014, doi: 10.1155/2014/151479
GHK-Cu in Nature
modulated by GHK
age 20 to age 60
in cosmetic serums
Loren Pickart died on December 10, 2023. He was 85. He'd watched the cosmetic industry adopt his molecule for decades — listing it on labels, citing his research in marketing materials, and using it at concentrations so far below his documented effective range that the connection to his actual work was, functionally, decoration.
I wrote that decorative copy. I'm telling you this so the weight of it lands where it should.
"I'm guessing that the other peptide products I've used before didn't contain those ingredients in effective doses. In fact, the Deciem website throws shade at other peptide products for containing copper peptides 'in very small amounts.'"
— Jude Chao, Fifty Shades of SnailShe guessed right. The products didn't contain effective doses. What she didn't have was the inside knowledge that this wasn't a guess — it was a fact the brands already knew and had already priced into their margin models.
Now she has it. Now you do too.
What BioGlo Does Differently — From Someone Who Knows What Different Actually Means
I want to be careful here. "We're different" is the claim every brand makes. I wrote it myself, in slightly varied forms, for eleven years. So when I tell you BioGlo is different, I want to show you the specific decisions that make it true — not ask you to take the word of a former marketing executive who just spent several paragraphs explaining she spent a decade writing things she didn't believe.
These differences are structural. They're not language choices. You can't fake them with better copy.
Decision 1: The concentration is on the label. Not "copper peptide complex." Not "peptide-rich formula." 2% GHK-Cu. The actual number, on the bottle. This single decision eliminates every copywriting trick I just described — you can't write around a number that's already disclosed. In eleven years I never worked with a brand that voluntarily put an active concentration on the label. Not once.
Decision 2: The Certificate of Analysis is public. Linked on the product page. From a named independent lab. HPLC purity above 98%. Mass spectrometry confirming the copper-bound molecular weight. That's not a call any brand I worked with would have been comfortable with you making.
Decision 3: They publish the conflict guide. At 2% GHK-Cu, the Fenton reaction is a real consideration — copper ions plus ascorbic acid can generate a free radical cascade. Every brand using GHK-Cu at sub-therapeutic concentrations never mentions this, because at 5 ppm there isn't enough copper for the chemistry to matter. BioGlo published the guide. Which means there's enough of it in the bottle for it to.
How to Read the CoA Yourself
I'm going to teach you something the industry would prefer you not know how to do.
A Certificate of Analysis is a document from a testing lab confirming the identity, purity, and concentration of a compound in a given sample. Here's what to look for in BioGlo's — and in any CoA you encounter going forward:
The test method. Look for HPLC — high-performance liquid chromatography. Gold standard for purity and concentration in pharmaceutical and cosmetic testing.
The purity figure. Above 98% means the compound is what it claims to be. If the figure is missing entirely, the document confirms identity but not purity. Different things.
The concentration figure. BioGlo's CoA confirms 2% GHK-Cu by mass in the tested sample. Not 2% of a blend. 2% of the active molecule itself.
BioGlo's CoA passes all three. I checked each one — not because I want you to take my word for it, but because I want you to be able to check it yourself and know exactly what you're looking at when you do.
What Happened When I Used It for 12 Weeks
I want to be as precise about this as I've been about everything else.
I started using BioGlo after I found the CoA. PM only, as the conflict guide specifies. No vitamin C in my evening routine. No direct acids in the same slot. I moved my tretinoin to alternating nights.
Nothing visible. I wasn't concerned. I'd read the research — GHK-Cu doesn't work on a hydration timeline.
Texture. The word I keep coming back to is density. My skin felt less like a surface and more like something with depth behind it. I know the difference between what a good moisturizer does and what something structural feels like beginning to shift.
I took photos. The lines at the outer corners of my eyes — the ones I'd watched deepen steadily since I turned 38 — were less deep. Not gone. I'm not going to use the language I spent eleven years writing. Less deep. Measurably.
My sister asked if I'd done something. She didn't mean skincare. She meant a procedure. I hadn't. I told her what I was using. She asked me to send the link.
I went back to the research. The 12-week facial study on 67 women. I looked at my week-two photos and my week-twelve photos. What I saw in my own face was consistent with what the study documented. Not identical. Consistent.
No "twenty years younger." No doctor gasping. No miracle. Measurably less-deep lines at week seven, visible density improvement at week four, and a question from my sister at week ten that — in eleven years of skincare work — I'd only ever heard when someone had just had a procedure done.
This time I hadn't.
The Pricing — Run the Honest Math
I spent eleven years helping brands price products. I know how this works, so I'll just tell you.
Prestige skincare pricing is almost entirely disconnected from formulation cost. A $295 serum doesn't contain $295 worth of ingredients. It contains the margin required to support the retail markup, the influencer budget, the Sephora gondola placement fee, the PR agency retainer — plus the formulation, which in the copper peptide category is almost always the smallest line item.
Sub-therapeutic
No CoA
Floor of clinical window
not disclosed
third-party HPLC CoA
If you've spent $90 on NIOD, $32 on The Ordinary, and $52 on Paula's Choice, you've spent $174 on sub-therapeutic concentrations. Spending $49.99 on a verified 2% isn't a gamble. It's the first time the formulation cost is actually proportional to what's claimed on the label.
I know what things cost to make. BioGlo's price is consistent with a product that contains what it says it does. That's not something I could have said about most of what I was paid to sell.
The Guarantee — Why 90 Days Matters
A 30-day guarantee on a copper peptide serum is a brand betting you won't see results before the return window closes. I've been in the room where return window decisions get made. The conversation is always about minimizing returns — not about giving customers enough time to actually evaluate.
GHK-Cu compounds over twelve weeks. A brand offering thirty days on a twelve-week active is doing arithmetic that benefits them, not you.
BioGlo offers 90 days. Every dollar back if it doesn't work. No forms. The logic: GHK-Cu takes twelve weeks, here are ninety days, because that's when the science says you'll see it. If you don't, you get refunded. Because a product that didn't work doesn't deserve your money.
In eleven years of copy, I never once wrote that last sentence for any brand I worked with. It's the only guarantee language I've read that I actually believed.
My Honest Recommendation
I'm not going to tell you this is for everyone. I spent eleven years telling people products were for everyone and I'm done with that.
You've used copper peptide products before and seen nothing measurable. You're willing to wait twelve weeks for structural results. You want to verify the concentration yourself before spending anything. You're 30 to 60, your skin is changing, and you want a mechanism you can check rather than a claim you have to trust.
You want visible results in a week. You're pregnant or breastfeeding. You have a known copper sensitivity. You're not willing to adjust your vitamin C timing — morning vitamin C, evening BioGlo, full stop.
Read the CoA before you buy. It's on the product page. You don't need my word on this, or BioGlo's, or anyone else's. The document exists. The lab exists. The concentration is there. Check it yourself.
Then — if it checks out, and it will — give it ninety days.
I spent eleven years helping this industry avoid exactly that kind of accountability. Finding a brand that invites it is not something I was willing to walk past without saying something.
So. Here I am.